vorasidenib
servier
['vorasidenib', 'indigo']
vorasidenib significantly delayed tumor growth in patients with low-grade #glioma, according to findings from the phase 3 indigo trial presented at #asco2023. | 
Oncology news and insights from leading researchers and cancer centers.